{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:29:32Z","timestamp":1787164172720,"version":"build-2736575974"},"reference-count":17,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.15119","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T08:14:59Z","timestamp":1748592899000},"page":"1-7","source":"Crossref","is-referenced-by-count":1,"title":["Real\u2011world evidence of imatinib treatment in younger and older patients with chronic myeloid leukaemia: A retrospective single centre analysis"],"prefix":"10.3892","volume":"30","author":[{"given":"Rebecca","family":"Graf","sequence":"first","affiliation":[{"name":"Karl Landsteiner University of Health Sciences, A-3500 Krems, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Kreye","sequence":"additional","affiliation":[{"name":"Karl Landsteiner University of Health Sciences, A-3500 Krems, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Pecherstorfer","sequence":"additional","affiliation":[{"name":"Karl Landsteiner University of Health Sciences, A-3500 Krems, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Singer","sequence":"additional","affiliation":[{"name":"Karl Landsteiner University of Health Sciences, A-3500 Krems, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"key20250703130947_b1-ol-30-2-15119","doi-asserted-by":"publisher","first-page":"34220074","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukaemia","volume":"370","author":"Hehlmann","journal-title":"Lancet"},{"key":"key20250703130947_b2-ol-30-2-15119","doi-asserted-by":"publisher","first-page":"S241","DOI":"10.1007\/s00277-015-2314-2","article-title":"Epidemiology of chronic myeloid leukaemia: An update","volume":"94","author":"Hoglund","year":"2015","journal-title":"Ann Hematol"},{"key":"key20250703130947_b3-ol-30-2-15119","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40164-020-00185-z","article-title":"Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: A population-based epidemiologic study","volume":"9","author":"Ning","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"key20250703130947_b4-ol-30-2-15119","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1056\/NEJM198810133191506","article-title":"The molecular genetics of philadelphia chromosome-positive leukemias","volume":"319","author":"Kurzrock","year":"1988","journal-title":"N Engl J Med"},{"key":"key20250703130947_b5-ol-30-2-15119","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/ajh.10364","article-title":"Imatinib in philadelphia chromosome-positive chronic phase cml patients: Molecular and cytogenetic response rates and prediction of clinical outcome","volume":"73","author":"Le Coutre","year":"2003","journal-title":"Am J Hematol"},{"key":"key20250703130947_b6-ol-30-2-15119","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6004\/jnccn.2024.0051","article-title":"Chronic myeloid leukemia, version 2.2024, nccn clinical practice guidelines in oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"key20250703130947_b7-ol-30-2-15119","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1158\/1078-0432.CCR-13-1988","article-title":"Deep molecular response in chronic myeloid leukemia: The new goal of therapy?","volume":"20","author":"Mahon","year":"2014","journal-title":"Clin Cancer Res"},{"key":"key20250703130947_b8-ol-30-2-15119","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2147\/JBM.S382090","article-title":"Chronic myeloid leukemia, from pathophysiology to treatment-free remission: A narrative literature review","volume":"14","author":"Rinaldi","year":"2023","journal-title":"J Blood Med"},{"key":"key20250703130947_b9-ol-30-2-15119","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/1097-0142(197204)29:4<1052::AID-CNCR2820290454>3.0.CO;2-7","article-title":"Hydroxyurea therapy in chronic myelogenous leukemia","volume":"29","author":"Kennedy","year":"1972","journal-title":"Cancer"},{"key":"key20250703130947_b10-ol-30-2-15119","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/annonc\/mdu490","article-title":"Differences among young adults, adults and elderly chronic myeloid leukemia patients","volume":"26","author":"Castagnetti","year":"2015","journal-title":"Ann Oncol"},{"key":"key20250703130947_b11-ol-30-2-15119","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","article-title":"Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: Results of the randomized CML study IV","volume":"126","author":"Saussele","year":"2015","journal-title":"Blood"},{"key":"key20250703130947_b12-ol-30-2-15119","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/cncr.11629","article-title":"Effects of age on prognosis with imatinib mesylate therapy for patients with philadelphia chromosome-positive chronic myelogenous leukemia","volume":"98","author":"Cortes","year":"2003","journal-title":"Cancer"},{"key":"key20250703130947_b13-ol-30-2-15119","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in cml over a period of 10 years: Data from the randomized cml-study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"},{"key":"key20250703130947_b14-ol-30-2-15119","doi-asserted-by":"publisher","first-page":"e01005","DOI":"10.1002\/prp2.1005","article-title":"Real-world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An australian experience","volume":"10","author":"Adattini","year":"2022","journal-title":"Pharmacol Res Perspect"},{"key":"key20250703130947_b15-ol-30-2-15119","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1182\/blood-2010-12-324228","article-title":"Frontline imatinib treatment of chronic myeloid leukemia: No impact of age on outcome, a survey by the GIMEMA CML working party","volume":"117","author":"Gugliotta","year":"2011","journal-title":"Blood"},{"key":"key20250703130947_b16-ol-30-2-15119","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"key":"key20250703130947_b17-ol-30-2-15119","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-021-01306-1","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: Enestnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T06:09:53Z","timestamp":1751522993000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.15119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":17,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,5,30]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.15119","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]}}}